New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
04:54 EDTINOInovio's HBV therapeutic vaccine generated strong T cell responses
Inovio Pharmaceuticals announced that its synthetic hepatitis B, or HBV, therapeutic vaccine generated strong T cell responses that eliminated targeted liver cells in mice. This data points to the DNA vaccine's potential to clear HBV infection and thereby prevent liver cancer in humans, an encouraging development given that nearly one-third of the world's population is infected with hepatitis B, with 400 million at risk of developing liver cancer. In the study, Inovio researchers and collaborators constructed a DNA vaccine encoding an HBV core antigen using the SynCon vaccine technology and administered it via Inovio's proprietary electroporation-based delivery technology. Researchers observed that the vaccine induced strong "killer" T cells in an animal model. Importantly, those killer T cells, while found systemically, were also present in the liver and provided clearance of HBV antigen-expressing liver cells without inducing liver damage. The company is also investigating additional HBV antigens to develop a multi-component vaccine that can provide the host immune system multiple targets to clear the hepatitis B virus and infected liver cells.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
08:41 EDTINOInovio announces dMAb targeting dengue virus provided protection in mice
Subscribe for More Information
July 27, 2015
08:10 EDTINOInovio initiates clinical trial of INO-5150 DNA immunotherapy
Subscribe for More Information
July 23, 2015
08:18 EDTINOInovio, EORTC to collaborate on Phase 2 cervical cancer trial
Inovio announced it is collaborating with the European Organization for Research and Treatment of Cancer, or EORTC, to evaluate Inovio's immunotherapy, INO-3112, in combination with traditional chemo-radiotherapy for the treatment of patients with locally advanced stage cervical cancer. The trial, primarily funded by the EORTC, is expected to begin by the end of the year. A partnership with the EORTC will offer Inovio clinical trial efficiency and speed in recruiting patients in Europe and in obtaining and analyzing results. The EORTC encompasses all aspects of cancer research, from translational research and new drug development to large phase III clinical trials and meta-analyses. EORTC is the only organization which carries out clinical studies throughout Europe for all types of cancer. Collaboration with the EORTC also leverages their connections to a network of more than 2,500 pre-clinical scientists and oncologists in more than 300 hospitals in over 30 countries.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use